LYMPHOMA, B-CELL

This study is for adults with B-cell or T-cell lymphoma that has returned or stopped responding to at least two prior treatments. The drug, STP938, blocks a protein cancer cells need to grow. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it …

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This early-stage study tests whether adding either iberdomide or CC-99282 to standard chemotherapy (R-CHOP) can safely treat people with untreated aggressive B-cell lymphoma. About 224 adults will take part. The main goals are to find the best dose and check for side effects, whi…

This study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and…

This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…

This study tests whether a blood test (ctDNA) can help doctors choose the right treatment for people with a type of lymphoma that happens after an organ transplant (PTLD). About 30 participants will be split into low-risk and high-risk groups. Low-risk patients will get only the …

This early-phase trial is testing an oral drug called BTM-3566 in 24 adults with relapsed or refractory B-cell lymphoma. The main goals are to find a safe dose and see if the drug can slow or stop the cancer. Participants take the drug for 7 days, then have 7 days off, and visit …

This study looks at whether adding early palliative care to standard treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will be randomly assigned to receive either usual care alone or usual care plus ear…

This study observes older patients (60+) receiving standard CAR-T therapy for blood cancers. Researchers track how treatment affects daily activities, thinking skills, and overall quality of life. No extra treatments are given—just careful monitoring to learn more about patient e…

This study is testing whether a new blood test (PhasED-seq) can detect leftover cancer DNA in real time during standard chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL). For patients whose blood shows no cancer DNA halfway through treatment, doctors will sho…

This study looks at families where at least two living blood relatives have a blood cancer like lymphoma, leukemia, or multiple myeloma. Researchers want to understand how genetics and environmental factors contribute to these cancers. The goal is to identify inherited risks that…

This study is testing a new communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors better discuss the diagnosis and plan future care with their patients. About 48 people (doctors and patients) will take part to…

This study looks at whether CAR-T cell therapy, a new immunotherapy for blood cancers like leukemia and lymphoma, can cause early heart problems. Researchers will measure heart function with ultrasound before and a few days after treatment in 60 patients. The goal is to find out …